On the afternoon of September 11, academician Moshe Szyf, founder of Hong Kong Gepi Therapeutics Ltd (HKG), executive directors Ye Xiang and Ban Shiqiang, China marketing director Wang Ying and companies visited Guangzhou Fuda Cancer Hospital and attended a symposium with hospital experts. Hospital president general Xu Kecheng, president Niu Lizhi, vice president Liang Bing, and directors of relevant departments attended the symposium. The two parties jointly discussed issues related to early cancer screening and diagnosis.
Before the symposium, Academician Moshe Szyf and companies, accompanied by Prof. Xu, had a tour around the hospital and formed a deeper understanding of the hospital, especially in cancer diagnosis and treatment, distinguishing anti-cancer technics, cancer-control concepts , and patient services.
After the tour, the two parties had an in-depth conversation in early screening and diagnosis of cancer. As the pioneer of methylation/epigenetics, Academician Moshe Szyf has conducted research on early cancer screening for nearly 40 years. During the conversation, Moshe introduced the revolution that epigenetic technology has brought to clinical medicine. He vividly explained the relationship between epigenetics and DNA methylation while using abundant experimental data to verify its possibility and reliability in early discovery and diagnosis, as well as treatment.
Forum site
Chief Dean Xu Kecheng extended a warm welcome to the arrival of Academician Moses Sifu and his delegation. He said that early screening and early diagnosis are important links in cancer prevention and treatment, and are also key breakthroughs in current cancer treatment. As a national key clinical cancer hospital, Guangzhou Fuda Cancer Hospital has been committed to providing high-quality medical services to cancer patients. It is hoped that through this exchange, we can further strengthen cooperation, jointly promote the development of research and application of early cancer diagnosis technology , and improve the treatment of disease. The ability and level of early detection can improve patient prognosis and contribute to the health of the people .
